2 not yet recruiting, 1 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow WGI-0301: new trials by email Literature Review of WGI-0301 trials Research Report on WGI-0301
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC WGI-0301, Lenvatinb - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang Haichang Biotech Co., Ltd. | 80 | 2026-09-01 | 2026-09-15 |
| Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC WGI-0301, Nivolumab (240 mg) - Hepato Cellular Carcinoma (HCC), Renal Cell Cancer | Phase 2 | Not yet recruiting | Zhejiang Haichang Biotech Co., Ltd. | 230 | 2026-06-01 | 2026-03-27 |
| A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors WGI-0301 - Advanced Solid Tumors | Phase 1 | Unknown | Zhejiang Haichang Biotech Co., Ltd. | 24 | 2022-08-01 | 2023-09-26 |
Zhejiang Haichang Biotech Co., Ltd. (3)
United States (2) · China (1)